Key result
Non-selective NSAIDs and COX-2 inhibitors are linked to adverse cardiorenal and pro-thrombotic effects.
Why the study?
The cardiorenal harmful effects of some nsNSAIDs and COX-2 inhibitors are well described but the mechanisms and class-specificity remain unclear.
Do nsNSAIDs and COX-2 inhibitors increase the risk of adverse cardiorenal effects in patients with musculoskeletal conditions?
Do nsNSAIDs and COX-2 inhibitors increase the risk of adverse cardiorenal effects in patients with musculoskeletal conditions?
This review highlights the significant cardiorenal risks associated with both non-selective NSAIDs and COX-2 inhibitors, emphasizing the need for caution, especially in high-risk populations.
Answers are grounded in this paper and cite their sources.
Urges vigilance with NSAID use in cardiovascular patients; leaves open precise risk estimates from randomized data.
The non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) and cyclooxygenase-2 (COX-2) inhibitors are commonly utilized agents for musculoskeletal conditions. The harmful cardiorenal effects of some nsNSAIDs are well described and thought to be related to inhibition of prostanoid synthesis. Since the non-specific inhibition of both cyclooxygenase enzymes was associated with a higher incidence of gastrointestinal side effects, the selective targeting of the COX-2 enzymes with the COX-2 inhibitors promised and delivered a lower incidence of gastrointestinal side effects. However, the COX-2 inhibitors have not been found to be bereft of cardiorenal side effects. Indeed, some of these agents lead to increased blood pressure, an excessive risk of congestive heart failure and pro-thrombotic effects, especially in high risk populations. These deletrious effects, however, may not be class-specific and possibly related to pharmacokinetics, enzyme specificity and endothelium effects. This article also reviews the body of literature linking the nsNSAIDs and COX-2 inhibitors with important adverse cardiorenal effects and their putative mechanisms.
No takes yet. Share an insight, caveat, or question.
Aneja et al. (2008) conducted a review in Musculoskeletal conditions. nsNSAIDs and COX-2 inhibitors was evaluated. Non-selective NSAIDs and COX-2 inhibitors are associated with adverse cardiorenal effects, including increased blood pressure, congestive heart failure, and pro-thrombotic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: